These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27660709)

  • 21. Grover's disease secondarily infected with herpes simplex virus and Staphylococcus aureus: case report and review.
    Bunce PA; Stanford DG
    Australas J Dermatol; 2013 Nov; 54(4):e88-91. PubMed ID: 23013197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
    Makarious D; Horwood K; Coward JIG
    Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Grover's disease associated with Sarcoptes scabiei.
    Kaddu S; Müllegger RR; Kerl H
    Dermatology; 2001; 202(3):252-4. PubMed ID: 11385234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Grover's disease in patients with chronic renal failure receiving hemodialysis: clinicopathologic review of 4 cases.
    Casanova JM; Pujol RM; Taberner R; Egido R; Fernández E; Alomar A
    J Am Acad Dermatol; 1999 Dec; 41(6):1029-33. PubMed ID: 10570394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementing Grover's on AES-based AEAD schemes.
    Mandal S; Anand R; Rahman M; Sarkar S; Isobe T
    Sci Rep; 2024 Sep; 14(1):21105. PubMed ID: 39256404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
    Oh DY; Cham J; Zhang L; Fong G; Kwek SS; Klinger M; Faham M; Fong L
    Cancer Res; 2017 Mar; 77(6):1322-1330. PubMed ID: 28031229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
    Gao J; He Q; Subudhi S; Aparicio A; Zurita-Saavedra A; Lee DH; Jimenez C; Suarez-Almazor M; Sharma P
    Oncogene; 2015 Oct; 34(43):5411-7. PubMed ID: 25659583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
    Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
    J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism.
    Win MA; Thein KZ; Qdaisat A; Yeung SJ
    Am J Emerg Med; 2017 Jul; 35(7):1039.e5-1039.e7. PubMed ID: 28363614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basis for a neuronal version of Grover's quantum algorithm.
    Clark KB
    Front Mol Neurosci; 2014; 7():29. PubMed ID: 24860419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of Toxicities of Immune Checkpoint Inhibitors].
    Horio Y
    Gan To Kagaku Ryoho; 2017 Mar; 44(3):185-190. PubMed ID: 28292987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Grover's disease following hemodialysis in a patient with renal failure].
    Moderer M; Korting HC; Yazdi A
    J Dtsch Dermatol Ges; 2004 Mar; 2(3):203-5. PubMed ID: 16281638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.
    Papavasileiou E; Prasad S; Freitag SK; Sobrin L; Lobo AM
    Ocul Immunol Inflamm; 2016; 24(2):140-6. PubMed ID: 25760920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
    Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
    Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
    Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unusual pulmonary toxicity of ipilimumab treated by macrolides.
    Mailleux M; Cornélis F; Colin GC; Baurain JF
    Acta Clin Belg; 2015 Dec; 70(6):442-4. PubMed ID: 26790556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
    Faje A
    Pituitary; 2016 Feb; 19(1):82-92. PubMed ID: 26186958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.